Sun Pharma gets SAHPRA approval for generic semaglutide

Sun Pharma Industries received approval from the South Africa — South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. The company plans to launch the product in the coming days as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL). South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. The approval reflects Sun Pharma's ability to develop complex generic medicines meeting stringent quality standards across different markets. The company emphasized that South Africa faces a growing burden of type 2 diabetes driven by rapid urbanization and changing lifestyles, and improving access to effective therapies is important for addressing this national health challenge.